rindopepimut

06/01/2015 - "A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study."
10/01/2017 - "Rindopepimut did not increase survival in patients with newly diagnosed glioblastoma. "
01/01/2017 - "Prospect of rindopepimut in the treatment of glioblastoma."
01/01/2014 - "Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme."
10/01/2017 - "Combination approaches potentially including rindopepimut might be required to show efficacy of immunotherapy in glioblastoma. "

12/01/2010 - "Preclinical studies demonstrated lasting tumor regression and increased survival times, as well as efficient generation of EGFRvIII-specific humoral and cellular immune responses, in animals expressing EGFRvIII and vaccinated with rindopepimut. "
01/01/2017 - "The EGFRvIII neoantigen is exclusively present on GBM cells, providing rindopepimut tumor-specific activity. "
03/01/2013 - "Several phase I and phase II clinical trials have demonstrated that vaccination with rindopepimut is safe, well tolerated and produces a highly potent immune response that effectively eradicates EGFRvIII-expressing tumor cells, leading to a 73% increase in survival among patients with newly diagnosed glioblastoma. "
01/01/2016 - "Rindopepimut activates a specific immune response against tumor cells harboring the EGFRvIII protein. "
01/01/2020 - "Rindopepimut is a vaccine targeting the tumor-specific EGF driver mutation, EGFRvIII. "

03/01/2013 - "Rindopepimut is currently undergoing evaluation in a phase III international trial for newly diagnosed glioblastoma and is under clinical investigation for recurrent glioblastoma and pediatric brain stem gliomas."
01/01/2016 - "Immunotherapy is an emerging and promising therapeutic approach to glioma and the EGFRvIII vaccine, rindopepimut, is the first immunotherapeutic drug to enter Phase III clinical trials for glioblastoma. "
04/01/2009 - "Specifically, the database is searched using the following keywords, with various combinations: glioma, low-grade, anaplastic, astrocytoma, oligodendroglioma, oligoastrocytoma, glioblastoma multiforme, chemotherapy, radiation, new concepts, phase III, MGMT, CDX-110 (Celldex), temozolomide, 1p/19q deletion, and bevacizumab."

10/01/2017 - "16 deaths in the study were caused by adverse events (nine [4%] in the rindopepimut group and seven [3%] in the control group), of which one-a pulmonary embolism in a 64-year-old male patient after 11 months of treatment-was assessed as potentially related to rindopepimut. "

10/01/2017 - "The most common grade 3-4 adverse events for all 369 treated patients in the rindopepimut group versus 372 treated patients in the control group were: thrombocytopenia (32 [9%] vs 23 [6%]), fatigue (six [2%] vs 19 [5%]), brain oedema (eight [2%] vs 11 [3%]), seizure (nine [2%] vs eight [2%]), and headache (six [2%] vs ten [3%]). "